Results 181 to 190 of about 72,801 (208)

Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?

Nature Reviews Clinical Oncology, 2021
Michael Karin
exaly  

Anti-obesity drug discovery: advances and challenges

Nature Reviews Drug Discovery, 2021
Timo D Müller, Matthias Blüher, Matthias Tschoep   +2 more
exaly  

Anti-Neutrophil Cytoplasmic Antibody Measurement

2020
openaire   +1 more source

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

Nature Reviews Clinical Oncology, 2018
Kabir A Khan, Robert S Kerbel
exaly  

Anti-CRISPR: discovery, mechanism and function

Nature Reviews Microbiology, 2017
April Pawluk, Alan R Davidson, Karen L Maxwell   +2 more
exaly  

New avenues for anti-epileptic drug discovery and development

Nature Reviews Drug Discovery, 2013
Wolfgang Löscher
exaly  

Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in Wegener's Granulomatosis

The International Journal of Artificial Organs, 1989
Bambery, P, Chugh, KS
openaire   +2 more sources

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

Cancer Cell, 2019
Tuba N Gide, Camelia Quek, Alexander M Menzies   +2 more
exaly  

[Anti-neutrophilic cytoplasmic antibodies (ANCA)].

Der Internist, 1995
W H, Schmitt, W L, Gross
openaire   +1 more source

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Nature Reviews Clinical Oncology, 2016
Celine Boutros, Ahmad A Tarhini, Olivier Lambotte   +2 more
exaly